News headlines about AxoGen (NASDAQ:AXGN) have been trending positive on Saturday, AlphaOne Sentiment reports. The research firm, a division of Accern, ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AxoGen earned a news impact score of 0.35 on AlphaOne’s scale. AlphaOne also gave media stories about the medical equipment provider an impact score of 99 out of 100, meaning that recent news coverage is extremely likely to have an effect on the stock’s share price in the next few days.
AXGN has been the subject of several analyst reports. Roth Capital initiated coverage on AxoGen in a research report on Monday, March 6th. They set a “buy” rating and a $14.50 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $14.00 target price (down from $17.00) on shares of AxoGen in a research report on Friday.
Shares of AxoGen (NASDAQ:AXGN) traded up 6.12% on Friday, reaching $14.75. The company had a trading volume of 489,090 shares. The company’s 50-day moving average is $12.01 and its 200-day moving average is $10.15. The company’s market capitalization is $488.15 million. AxoGen has a one year low of $5.30 and a one year high of $15.12.
AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Thursday, May 4th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. AxoGen had a negative net margin of 33.02% and a negative return on equity of 292.94%. The business had revenue of $12.24 million for the quarter, compared to analysts’ expectations of $11.83 million. Equities research analysts predict that AxoGen will post ($0.31) earnings per share for the current year.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.